Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) produces dose-related therapeutic and toxic effects; however, relationships between its pharmacokinetics and pharmacodynamics have not been extensively evaluated. The following studies were undertaken t o investigate patterns in the disposition of rHuGM-CSF administered after high-dose chemotherapy (cyclophosphamide, cisplatin, carmustine) and autologous bone marrow support. Continuous 14 or 21 day intravenous infusions or daily 4-hour infusions were studied at doses of 1.2 t o 19.2 Fg/ kg/d. GM-CSF was measured by an enzyme-linked immunosorbent assay from serum and urine samples collected throughout drug administration. Pharmacokinetic parameters were determined by compartmental (4-hour infusions) or noncompartmental methods (continuous infusions). GM-CSF was rapidly eliminated from the serum. Average systemic
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DMINISTRATION of recombinant human granulo-
A cyte-macrophage colony-stimulating factor (rHuGM-CSF) to patients receiving high-dose chemotherapy with autologous bone marrow support will accelerate hematopoietic Dose-related therapeutic and toxic effects of this glycoprotein have been described in human~.l-~ Preliminary evaluation of rHuGM-CSF pharmacokinetic characteristics indicates a rapid disappearance of drug from serum after intravenous (IV) Conversely, subcutaneous dosing yields sustained serum concentrations of greater than 1 ng/mL up to 12 hours after administration of 10 ~g / k g .~-~ This report describes the pharmacokinetic characteristics of rHuGM-CSF administered at various dosage levels as either a continuous or a short IV infusion and evaluates relationships between these variables and pharmacodynamic effects. Clinical results of these phase 1-11 studies were previously d e~c r i b e d .~,~
MATERIALS AND METHODS
All patients in this report received rHuGM-CSF subsequent to high-dose chemotherapy and autologous bone marrow support for the treatment of stage 11-IV breast cancer or metastatic melanoma.
Patients with serious renal dysfunction (serum creatinine > 1.5 mg/dL; creatinine clearance < 60 mL/min) or liver dysfunction (serum total bilirubin > 2 mg/dL; serum aspartate aminotransferase >2.5 times normal) were excluded from receiving this chemotherapy regimen. The ablative treatment included cyclophosphamide (5,625 mg/m*), carmustine (600 mg/m2), and cisplatin (165 mg/m2) administered over the course of 4 days (day -6 to day -3), as previously described? Autologous bone marrow was infused 4 days after the end of chemotherapy (day +l). Glycosylated rHuGM-CSF was derived from a Chinese hamster ovary expression system (4.40 or 7.78 x 103 U/kg aglycoprotein for patients with unique patient number [UPN] < 152 or > 151, respectively; Sandoz/Schering-Plough, Basel, Switzerland). All doses of rHuGM-CSF administered to an individual patient were obtained from the same lot (identical specific activity). The first cohort of patients received rHuGM-CSF by continuous IV infusion at escalating dosages between patients for 14 or 21 days. A subsequent cohort received daily 4-hour infusions. The doses in exposure increased with dose, although wide interpatient variability was evident. Approximately one half of the patients receiving continuous infusions demonstrated increasing GM-CSF clearance that corresponded t o the appearance of white blood cells in the periphery. Conversely, clearance decreased in those experiencing renal dysfunction during the infusion. The percentage of a GM-CSF dose found in 24-hour urine collections was substantially reduced in the latter group. A subset of patients who developed renal dysfunction also experienced significant hypotension. Rapidly increasing serum GM-CSF concentrations corresponded t o the hypotensive episodes. GM-CSF serum concentration monitoring may be useful for evaluation of therapeutic and toxic effects in patients receiving high-dose chemotherapy with autologous bone marrow support. 0 1992 by The American Society of Hematology.
this group were also escalated between patients and therapy continued for 21 days. rHuGM-CSF infusions were initiated 3 hours after marrow administration (day +l). Lyophilized drug was reconstituted in sterile water and added to 500 mL 5% dextrose/ 0.45% saline/O.l% albumin. Dosages expressed in this report are in unglycosylated equivalents.
Serum samples were obtained for evaluation of GM-CSF concentration on the following days of therapy: day -6 (before chemotherapy), day +1 (before marrow reinfusion), every other day during rHuGM-CSF administration, and on the final day of rHuGM-CSF administration. Sampling times varied with administration schedule. Single daily samples were obtained during the continuous infusion regimens, whereas samples from preinfusion and immediately postinfusion were collected from the patients receiving the daily 4-hour regimen. In addition, samples were collected at 5, 10, 15, 20, 30, 45, 60, 120, 240, and 360 minutes after completing infusions on the final day of the regimens. The latter samples were also obtained in some patients on day 15 of a 21-day/4-hour infusion regimen. A 24-hour urine collection was obtained after the start of the daily 4-hour IV infusion in several patients on the first and last day of rHuGM-CSF administration.
Immunoreactive GM-CSF was measured using a double antibody sandwich technique. Murine monoclonal antihuman GM-CSF antibody (MoAb) 108g9 was coated onto plastic microtiter well plates and used as a capture antibody. After blocking the plate with 1% bovine serum albumin in TBS (tris-buffered saline; 10 1136 PETROS ET AL mmol/L tris, 150 mmol/L NaCl, pH 7.5) for 2 hours, 100-pL test samples (serum or urine) and standards/controls (rHuGM-CSF in phosphate-buffered saline [PBS]), were added and further incubated at 4°C overnight. The plate was washed, and 100 pL of a mixture of three biotinylated anti-GM-CSF MoAbs (3034, 3092, and 4117,100 FL per well, each antibody at 3 ~g / m L )~ was added and incubated at room temperature for 2 hours. After further washing steps, 100 FL of extraviridin-alkaline phosphatase conjugate (Sigma Chemical Co, St Louis MO; 1:3,000) was added and incubated at room temperature for a further 1 to 2 hours. After washing, the plate was developed with 100 pL per well of alkaline phosphatase substrate solution (Bio-Rad, Richmond, CA) and the plate read on a microplate reader with a 405-nm interface filter. All standards and serum or urine samples were diluted in PBS to produce results in the linear range of this assay.
Selection of the appropriate pharmacokinetic model and initial parameter estimations for each patient were performed by curve stripping (RSTRIP V.4.03; MicroMath, Salt Lake City, UT). Subsequent evaluation of individual data sets was conducted using a one-compartment model with zero-order input and a first-order elimination process (PCNONLIN V.3.0; Statistical Consultants, Lexington, KY). Systemic drug clearance was determined in those patients receiving rHuGM-CSF by continuous IV infusion using noncompartmental methods as described by the following equation: Clearance = Infusion Rate/Steady-State Serum Concentration.
Statistical analysis was performed using the Wilcoxon test for paired analysis and the Mann-Whitney U test for nonpaired group comparison. Table 1 . These values should be considered "apparent" because current analytical methods cannot distinguish endogenously produced GM-CSF from exogenously administered drug. GM-CSF serum concentrations typically approached baseline levels by 2 hours postinfusion as is evident by an average half-life of 69 minutes and volume of distribution approximating that of plasma. Average systemic exposure to GM-CSF (as measured by either the area under the concentration x time curve or maximal serum concentration) increased with dose; however, considerable inter-and intra-patient variability in systemic clearance was evident (Table 1) .
RESULTS

All patients in this trial
Twenty-four-hour urine collections on the first and last day of rHuGM-CSF administration were analyzed in four patients receiving 21-day, 4-hour infusions of 11.1 Fg/kg/d. Approximately 18% to 34% of the dose could be accounted for in the 24-hour urine collection on day 1; however, by day 21 two patients excreted less than 5% of the dose within 24 hours. These two patients had serum creatinine values greater than two times baseline, whereas serum creatinine in the two patients with relatively stable GM-CSF urinary For (Fig 1) .
All patients in the continuous IV infusion group experienced absolute neutropenia from the ablative therapy with WBC count <250/mm3; however, by end of the treatment regimen WBC count was >1,OOO/mm3 in all patients receiving at least 14 days of therapy beyond the first dosing level. Evaluation of rHuGM-CSF systemic clearance over the course of therapy in patients receiving rHuGM-CSF by continuous infusion showed even greater intra-and interpatient variability than the intermittent infusion regimen. A discernable trend could be shown in some patients when GM-CSF clearance was related to WBC count, with higher WBC counts corresponding to escalated clearance values (eg, Fig 2) . Systematic evaluation of this information was determined by segregating the clearance data based on WBC recovery. Clearance estimates obtained on days 4 to 8 of continuous infusion were averaged for each patient because the WBC count in all patients was <250/mm3 during this period. Similarly, noncompartmental clearance was estimated on the last day of continuous infusion when WBC count was > l,W/mm3. The median clearance when leukocytes were <250/mm3 was 9.93 mL/h/kg whereas with >l,000/mm3 the median clearance was 14.86 mL/ h/kg (P = .21; Table 2 ). Forty-two percent (8 of 19) of the interpretable patients showed a greater than 20% increase in clearance when segregated in this manner.
Segregation of these data based on renal function (estimated creatinine clearance) describes a group of patients with increasing GM-CSF serum concentrations from those with WBC-related (increasing) clearance (Fig 3) . The median increase in GM-CSF clearance for the group without renal dysfunction was 12% (within-patient comparison: P = .036), whereas clearance in patients exhibiting renal dysfunction (serum creatinine > twice baseline value during therapy) actually decreased by 32% (group comparison: P = .0018).
Five patients in this report required vasopressor support (IV dopamine or phenylephrine) for severe hypotension (mean arterial pressure < 70 mm Hg) during continuous infusion of rHuGM-CSF. These patients were a subset of the group with renal dysfunction and each received at least 1 week of therapy with rHuGM-CSF before onset of hypotension. All of these patients had infusions prematurely discontinued at the onset of vasopressor support. (In addition, continuous infusion rHuGM-CSF was stopped early in another patient with renal dysfunction as well as new onset pleural and pericardial effusions.) Investigation of these patients' serum showed elevated concentrations of GM-CSF and a reduced clearance corresponding to the time of maximum toxicity in each of the five patients. While most of these cases were encountered at the two highest doses, one case occurred in a patient receiving only 5.55 pg/kg/d (UPN 193). This patient's steady-state serum concentration on the final day of infusion (day of minimum blood pressure) was 4-to 30-fold higher than the other three patients at that dosing level (Fig 4) .
DISCUSSION
Clinical utilization of rHuGM-CSF can alter the nature of chemotherapy-induced toxicities and allow delivery of a greater chemotherapy dose-intensity.lOJ1 Unfortunately, rHuGM-CSF phase I studies have demonstrated doselimiting adverse effects including a capillary leak syndrome, serositis, and renal dysf~nction.~,~ Thus, evaluation of GM-CSF pharmacokinetic disposition may show factors that could improve tolerance and optimize efficacy in the individual patient.
Serial serum concentrations of GM-CSF have been reported previously by several investigators, demonstrating rapid drug elimination after IV administrati~n.~,~ Serum concentrations in patients given 4-hour infusions in the present study are in agreement with previous observations as values approach baseline within 2 hours of drug discontinuation. We have applied formal pharmacokinetic modeling to further characterize individual patients' parameters. A one compartment model with zero-order absorption and For personal use only. on September 24, 2017. by guest www.bloodjournal.org From tFinal day of continuous infusion.
SGM-CSF concentration < 1 ng/mL. §Infusion discontinued early because of toxicity (renal dysfunction and severe hypotension n = 5; renal dysfunction and pleural/pericardial effusions n = 1).
first-order elimination processes best fit the data obtained when rHuGM-CSF was administered as a short IV infusion with postinfusion sampling. Average GM-CSF systemic exposure (as measured by the maximal serum concentration or area under the concentration x time curve) increased with dose; however, there was variability both between and within patients. UPN: 121, 131, 151, 153,  154, 157, 171, 177, 193) showed a decrease in systemic clearance (median decrease 32%; n = 9).
Apparent systemic rHuGM-CSF clearance during continuous IV infusion could be calculated from daily steady-state serum concentrations due to the relatively quick elimination profile. Inter-patient variability in systemic clearance for the continuous infusion regimen was higher than that encountered in patients receiving 4-hour infusions (coefficient of variation [CV] 120% and 65%, respectively) despite I l For personal use only. on September 24, 2017. by guest www.bloodjournal.org From comparison of values obtained only on the last day of therapy. These data, combined with extensive intra-patient variability in the continuous infusion group, prompted investigation of the relationship between drug clearance and peripheral WBC recovery in accordance with a receptor binding model. Segregation of data based on steadystate concentrations obtained during relative aplasia (WBC count < 250/mm3) and those obtained after evidence of marrow recovery (WBC count > l,000/mm3) was able to account for a substantial portion of this variability. The precise routes of GM-CSF elimination have not been extensively evaluated in humans. Blood and tissue proteases are thought to play a role in the disposition of recombinant proteins. Nonpathogenic variability in renal and/or hepatic function could account for a 3-to 10-fold inter-patient variance in clearance of some drugs; however, an alternative potential mechanism for recombinant proteins such as GM-CSF may be via receptor attachment and internalization. A similar phenomenon has been reported by Layton et a1.12 These investigators noted lower concentrations of rHuG-CSF associated with increased neutrophil counts in subjects administered the growth factor before chemotherapy compared with dosing during marrow aplasia. These data accentuate the potential influence of administration route on the disposition and excretion of recombinant growth factors.
Nine patients in the continuous infusion group experienced significant renal dysfunction (serum creatinine greater than two times baseline value) during the course of GM-CSF. In contrast to most patients without significant renal dysfunction, 89% of these patients demonstrated significantly lower clearance on the last day of therapy (Fig 3) . Thus, the relative importance of renal function in determination of serum GM-CSF disposition during continuous infusion may overshadow that of the proposed leukocytemediated mechanisms of clearance in our patient population.
The renal disposition of proteins similar in molecular weight to GM-CSF is thought to be characterized by glomerular filtration with subsequent tubular reabsorption and enzymatic degradation. 13 We conducted further investigation of the relation between renal function and GM-CSF clearance by analyzing the amount of immunoreactive GM-CSF-like activity present in urine collected over 24 hours in a subset of patients receiving 4-hour IV dosing. On initiation of therapy, approximately 30% of the daily dose could be found in the urine for all studied. On day 21 of drug administration patients without significant changes in serum creatinine continued to excrete approximately 30% of the daily dose in the urine. Acute alterations in renal tubular function resulting in increased excretion of potassium and magnesium are common with the cisplatin dosages used in this study. These changes may account for the high initial urinary excretion of GM-CSF noted in our patients. Cebon et all4 have also described a potential alteration in GM-CSF urinary excretion in patients exposed to cisplatin.
In contrast, our patients with a greater than twofold increase in serum creatinine during therapy excreted < 5% of the dose in 24-hour urine collections. These data are in accordance with the proposed excretion mechanism of glomerular filtration followed by tubular reabsorption and metabolism. Thus, not only may renal function be affected by rHuGM-CSF administratioq2 but it also may play an important role as a mechanism for GM-CSF elimination. Hypotension is a notable, acute adverse effect that can be attributed to rHuGM-CSF administration. Transient hypoxemia and hypotension are frequent "first-dose" effects; however, their occurrence with subsequent doses is limited.15 Pharmacokinetic disposition of GM-CSF in our patients with hypotension (a subset of the patients with renal dysfunction) also demonstrated accumulation of drug over time. Elevated serum concentrations were encountered at times of toxicity. Interestingly, one patient showed highly elevated concentrations in comparison with others receiving similar milligram-per-kilogram doses. Because concentrations were steadily increasing over several days, it is plausible that early identification of such phenomenon may enable dosage adjustment to perhaps avoid these effects, although clinical trials will be needed to address this issue before recommendations for routine clinical monitoring can be made.
Analytic methods in current clinical use (including those used in the present study) cannot distinguish between endogenous and recombinant GM-CSF. In addition, immunologic assays, such as the enzyme-linked immunosorbent assay, have the potential to overlook some structural alterations that could render the protein inactive. Unfortunately, alternative methods such as biologic assays are often too cumbersome for detailed clinical pharmacokinetic studies and may be influenced by endogenous inhibitors found in clinical samples.
The present data are derived from patients being treated with rHuGM-CSF (generic name regramostim) that was expressed from a Chinese hamster ovary cell line. Such expression produces a glycosylated protein that differs in structure from the currently marketed compound (sargramostim), which is expressed in yeast cells. The pharmacokinetic implications of altering the glycosylation pattern have not been comparatively evaluated in humans, thus caution should be exercised in extrapolation of these data.
Further study of rHuGM-CSF clinical pharmacokinetics should include evaluation of endogenous cytokines released secondary to its administration, and their role in toxicity. Simultaneous evaluation by sensitive and specific bioassays should be conducted to substantiate results obtained on immunologic assay. Development of models to describe the relationship of pharmacokinetics to response in these systems will aid in optimizing dosage regimens and may help to minimize toxicity.
